Sodium–glucose cotransporter-2 (SGLT2) inhibitors, originally developed for type 2 diabetes, have demonstrated beneficial effects on the metabolic and cardiovascular risk profile of patients with OSA. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.